ASSET PURCHASE AGREEMENT AMONG Saol International Limited, Saol BERMUDA limited, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., Saol US Inc., KAMADA LIMITED AND KAMADA INC. Dated as of November 22, 2021Asset Purchase Agreement • November 22nd, 2021 • Kamada LTD • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is entered into as of November 22, 2021 by and among Saol International Limited, a Bermuda limited company (“SIL”), Saol Bermuda Limited, a Bermuda limited company (“SBL”), Saol Therapeutics Research Limited, an Irish limited company (“STRL”), Saol Therapeutics Inc., a Delaware corporation (“STI”) and Saol US Inc., a Delaware corporation (“SUSI” and, together with SIL, SBL, STI and STRL, on a joint and several basis, the “Sellers” and each, individually, a “Seller”), and Kamada Limited, a company limited by shares incorporated in Israel (“Kamada”), and Kamada Inc., a Delaware corporation and a wholly owned subsidiary of Kamada (“Kamada Inc.”, and together with Kamada, the “Buyer”). Buyer and Sellers are each referred to herein as a “Party” and collectively herein as the “Parties.”
